Targeting specific mutations in lung cancer for better treatment options
Synthetic lethal targeting of KRAS/KEAP1 co-mutant non-small cell lung cancer
['FUNDING_R01'] · RUSH UNIVERSITY MEDICAL CENTER · NIH-10989208
This study is looking at a new treatment for people with non-small cell lung cancer that has specific mutations, using a combination of two drugs, LMK235 and AMG510, to help make the treatment more effective and hopefully improve outcomes for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUSH UNIVERSITY MEDICAL CENTER (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10989208 on ClinicalTrials.gov |
What this research studies
This research focuses on non-small cell lung cancer (NSCLC) that has both KRAS and KEAP1 mutations, which are often resistant to standard therapies. The study investigates the use of a drug called LMK235, which inhibits a protein known as HDAC4 that is crucial for the survival of these cancer cells. By combining LMK235 with another FDA-approved drug, AMG510, the research aims to enhance the effectiveness of treatment for patients with these specific mutations. The approach involves understanding how these drugs work together to induce cancer cell death, potentially leading to improved outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer that has both KRAS and KEAP1 mutations.
Not a fit: Patients with non-small cell lung cancer that do not have KRAS or KEAP1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with KRAS/KEAP1 co-mutant non-small cell lung cancer.
How similar studies have performed: Previous research has shown promising results with similar drug combinations in targeting specific mutations in cancer, indicating potential for success in this approach.
Where this research is happening
CHICAGO, UNITED STATES
- RUSH UNIVERSITY MEDICAL CENTER — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAKI, CARL G — RUSH UNIVERSITY MEDICAL CENTER
- Study coordinator: MAKI, CARL G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancer cell line, Cancers